Stockreport
With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns [Yahoo! Finance]
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
The top 8 shareholders own 51% of the company Recent sales by insiders A look at the shareholders of Allogene Therapeutics, Inc. ( NASDAQ:ALLO ) can tell us which group is most powerful. With 56% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's delve deeper into each type of owner of Allogene Therapeutics, beginning with the chart below. Check out our latest analysis for Allogene Therapeutics What Does The Institutional Ownership Tell Us About Allogene Therapeutics? Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often beco
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | ALLO | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
ALLO alerts
ALLO alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
NEWS
NEWS
- Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock? [Yahoo! Finance][Yahoo! Finance]
- Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse [Yahoo! Finance][Yahoo! Finance]
- Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse[GlobeNewswire]
- Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance][Yahoo! Finance]
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $11.00 price target on the stock.[MarketBeat]
- More
ALLO
SEC Filings
SEC Filings
- 6/20/24 - Form 4
- 6/18/24 - Form 144
- 6/11/24 - Form 3
- ALLO's page on the SEC website
- More